A-7387 inhibits bile acid transporter and blocks hepatitis infection

Nov. 21, 2023

Researchers from Ipsen Ltd. and affiliated organizations presented the discovery and preclinical characterization of a novel NTCP inhibitor, A-7387, being developed for the treatment of HBV and HDV infections.

BioWorld Science Conferences New compound American Association for the Study of Liver Diseases Gastrointestinal Infection

Today's news in brief

BioWorld

BioWorld briefs for Jan. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 10, 2025

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

Australia’s Celosia heads toward clinic with gene therapy for ALS

BioWorld

After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that...

Sangamo stock plunges as Pfizer leaves hemophilia partnership

BioWorld

Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A...

Upgrade your daily dose of biopharma and medtech news

A-7387 inhibits bile acid transporter and blocks hepatitis infection